IPRP Working Groups

The Bioequivalence Working Group for Generics (BEWGG) covers the application and interpretation of bioequivalence requirements as well as information and procedures for the assessment of

The Biosimilars Working Group (BWG) provides meaningful outcome to promote public health through more affordable biosimilar products.   Mandate 1. General considerations The

The Cell Therapy Working Group (CTWG)’s primary goals are open discussion and sharing of best practices for the regulation of cell and tissue-based therapies, as well as support of harmonization

This pilot project has been closed in November 2020.   The Information Sharing Working Group for Generics (IWGG) was a pilot for the sharing of information on the evaluation of Generic

The Gene Therapy Working Group (GTWG)’s objective is to discuss emerging scientific developments and concerns for the regulation of Gene Therapy (GT) products and to share regional updates in

The Identification of Medicinal Products Working Group (IDMPWG)’s work is to ensure the awareness and understanding of the IDMP standards by pharmaceutical regulators, to clarify how and why these

The Nanomedicines Working Group (NWG) works on the exchange of non-confidential information on nanomedicines and nanomaterials in drug products and borderline and combination products.  

The Pharmacovigilance Working Group (PVWG)  works to leverage knowledge-sharing and opportunities to advance collaboration in the area of pharmacovigilance between IPRP members.  

The Quality Working Group (QWG) identifies opportunities for regulatory convergence and information sharing by exchanging and discussing information from members’ organisation regarding issues of